bs_bs_banner
UROLOGICAL NOTES
2 Schafer M, Bauder-Wust U, Leotta K et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012; 2: 23. 3 Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging 2012; 39: 1085–6. 4 Roethke MC, Kuru TH, Afshar-Oromieh A, Schlemmer HP, Hadaschik BA, Fenchel M. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. Eur. Urol. 2013; 64: 862–4.
5 Drzezga A, Souvatzoglou M, Eiber M et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J. Nucl. Med. 2012; 53: 845–55. 6 Arce-Calisaya P, Souvatzoglou M, Eiber M et al. Sensitivity of PET/MRI to detect recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013; 40: 799. 7 Kuru TH, Roethke MC, Seidenader J et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J. Urol. 2013; 190: 1380–6.
Editorial Comment Editorial Comment to Positron emission tomography/magnetic resonance imaging with 68 Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging? Magnetic resonance imaging (MRI) is regarded to be the superior method for prostate cancer imaging. This holds especially true for multiparametric MRI of the prostate, where different imaging sequences are combined in order to maximize information on tumor anatomy and physiology. Positron emission tomography (PET) imaging of the prostate is able to add a metabolic feature to the multiparametric approach; and with the introduction of fully integrated PET/MRI scanners, a real multiparametric/metabolic imaging approach of prostate cancer has become possible for the first time. Since the first report of simultaneous PET/MRI of prostate cancer, further studies have been carried out in this field.1 It was shown that 18F and 11C choline PET/MRI carried out well in comparison to PET/ computed tomography in terms of lesion detection and correlation of standardized uptake values.2,3 Furthermore, these studies showed the clinical feasibility and robustness of the integrated PET/MRI system when applied to prostate cancer imaging. Whereas some groups focus on “classical” tracers for prostate cancer PET/MRI imaging, such as 11C or 18F choline, other study groups explore the potentials of a Gallium-labeled prostate-specific membrane antigen ligand (68Ga-PSMA-L), which is overexpressed in prostate carcinoma cells when compared with other tissues expressing PSMA. Afshar-Oromieh et al. reported on an improved detection rate of lesions of suspected recurrent prostate cancer and improved tumor-tobackground ratio when using 68Ga-PSMA-L compared with 18F choline.4 In this Urological Note, Maurer et al. report on their first clinical results with 68Ga-PSMA-L simultaneous PET/MRI imaging of patients with prostate cancer at different disease stages.5 Their study gives an interesting brief overview of potential fields of application of 68Ga-PSMA-L in prostate cancer imaging with integrated PET/MRI. From a clinical point of view, the presented examples summarize and highlight problem fields of prostate cancer diagnostics; for example, a patient with previous negative prostate biopsies, but strong suspicion of prostate cancer, where precise biopsy planning is of utmost importance. 1288
Although the studies with the “new” prostate cancer tracer are indeed promising, recent reports on 18F choline as a tracer for prostate cancer imaging with combined PET/MRI are also encouraging.6 Considering the present literature and the examples presented by Maurer et al., prostate cancer imaging with 68 Ga-PSMA-L is a hot topic, but further prospective studies to show the expected superiority are required. Axel Wetter M.D. Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany [email protected] DOI: 10.1111/iju.12596
Conflict of interest None declared.
References 1 Wetter A, Lipponer C, Nensa F et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest. Radiol. 2013; 48: 256–62. 2 Wetter A, Lipponer C, Nensa F et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2014; 41: 79–88. 3 Souvatzoglou M, Eiber M, Takei T et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013; 40: 1486–99. 4 Afshar-Oromieh A, Zechmann C, Malcher A et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2014; 41: 11–20. 5 Maurer T, Beer AJ, Wester HJ, Kübler H, Schwaiger M, Eiber M. Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int. J. Urol. 2014; 21: 1286–8. 6 De Perrot T, Rager O, Scheffler M et al. Potential of 18F-fluorcholine PET/MRI for prostate cancer imaging. Eur. J. Nucl. Med. Mol. Imaging 2014; 41: 1744–55. © 2014 The Japanese Urological Association
Copyright of International Journal of Urology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
UROLOGICAL NOTES
2 Schafer M, Bauder-Wust U, Leotta K et al. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012; 2: 23. 3 Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging 2012; 39: 1085–6. 4 Roethke MC, Kuru TH, Afshar-Oromieh A, Schlemmer HP, Hadaschik BA, Fenchel M. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. Eur. Urol. 2013; 64: 862–4.
5 Drzezga A, Souvatzoglou M, Eiber M et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J. Nucl. Med. 2012; 53: 845–55. 6 Arce-Calisaya P, Souvatzoglou M, Eiber M et al. Sensitivity of PET/MRI to detect recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013; 40: 799. 7 Kuru TH, Roethke MC, Seidenader J et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J. Urol. 2013; 190: 1380–6.
Editorial Comment Editorial Comment to Positron emission tomography/magnetic resonance imaging with 68 Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging? Magnetic resonance imaging (MRI) is regarded to be the superior method for prostate cancer imaging. This holds especially true for multiparametric MRI of the prostate, where different imaging sequences are combined in order to maximize information on tumor anatomy and physiology. Positron emission tomography (PET) imaging of the prostate is able to add a metabolic feature to the multiparametric approach; and with the introduction of fully integrated PET/MRI scanners, a real multiparametric/metabolic imaging approach of prostate cancer has become possible for the first time. Since the first report of simultaneous PET/MRI of prostate cancer, further studies have been carried out in this field.1 It was shown that 18F and 11C choline PET/MRI carried out well in comparison to PET/ computed tomography in terms of lesion detection and correlation of standardized uptake values.2,3 Furthermore, these studies showed the clinical feasibility and robustness of the integrated PET/MRI system when applied to prostate cancer imaging. Whereas some groups focus on “classical” tracers for prostate cancer PET/MRI imaging, such as 11C or 18F choline, other study groups explore the potentials of a Gallium-labeled prostate-specific membrane antigen ligand (68Ga-PSMA-L), which is overexpressed in prostate carcinoma cells when compared with other tissues expressing PSMA. Afshar-Oromieh et al. reported on an improved detection rate of lesions of suspected recurrent prostate cancer and improved tumor-tobackground ratio when using 68Ga-PSMA-L compared with 18F choline.4 In this Urological Note, Maurer et al. report on their first clinical results with 68Ga-PSMA-L simultaneous PET/MRI imaging of patients with prostate cancer at different disease stages.5 Their study gives an interesting brief overview of potential fields of application of 68Ga-PSMA-L in prostate cancer imaging with integrated PET/MRI. From a clinical point of view, the presented examples summarize and highlight problem fields of prostate cancer diagnostics; for example, a patient with previous negative prostate biopsies, but strong suspicion of prostate cancer, where precise biopsy planning is of utmost importance. 1288
Although the studies with the “new” prostate cancer tracer are indeed promising, recent reports on 18F choline as a tracer for prostate cancer imaging with combined PET/MRI are also encouraging.6 Considering the present literature and the examples presented by Maurer et al., prostate cancer imaging with 68 Ga-PSMA-L is a hot topic, but further prospective studies to show the expected superiority are required. Axel Wetter M.D. Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany [email protected] DOI: 10.1111/iju.12596
Conflict of interest None declared.
References 1 Wetter A, Lipponer C, Nensa F et al. Simultaneous 18F choline positron emission tomography/magnetic resonance imaging of the prostate: initial results. Invest. Radiol. 2013; 48: 256–62. 2 Wetter A, Lipponer C, Nensa F et al. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT. Eur. J. Nucl. Med. Mol. Imaging 2014; 41: 79–88. 3 Souvatzoglou M, Eiber M, Takei T et al. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013; 40: 1486–99. 4 Afshar-Oromieh A, Zechmann C, Malcher A et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2014; 41: 11–20. 5 Maurer T, Beer AJ, Wester HJ, Kübler H, Schwaiger M, Eiber M. Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: promising novel option in prostate cancer imaging? Int. J. Urol. 2014; 21: 1286–8. 6 De Perrot T, Rager O, Scheffler M et al. Potential of 18F-fluorcholine PET/MRI for prostate cancer imaging. Eur. J. Nucl. Med. Mol. Imaging 2014; 41: 1744–55. © 2014 The Japanese Urological Association
Copyright of International Journal of Urology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.
